Literature DB >> 22691390

TDP-43: a new player on the AD field?

Katherine L Youmans1, Benjamin Wolozin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22691390      PMCID： PMC3910368          DOI： 10.1016/j.expneurol.2012.05.018

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  111 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.

Authors:  D M Walsh; D M Hartley; Y Kusumoto; Y Fezoui; M M Condron; A Lomakin; G B Benedek; D J Selkoe; D B Teplow
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

3.  Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity.

Authors:  R Yan; M J Bienkowski; M E Shuck; H Miao; M C Tory; A M Pauley; J R Brashier; N C Stratman; W R Mathews; A E Buhl; D B Carter; A G Tomasselli; L A Parodi; R L Heinrikson; M E Gurney
Journal:  Nature       Date:  1999-12-02       Impact factor: 49.962

4.  Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation.

Authors:  Jessica W Wu; Leonid Breydo; J Mario Isas; Jerome Lee; Yurii G Kuznetsov; Ralf Langen; Charles Glabe
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

Review 5.  The frontotemporal syndromes of ALS. Clinicopathological correlates.

Authors:  Michael Joseph Strong; Wencheng Yang
Journal:  J Mol Neurosci       Date:  2011-08-02       Impact factor: 3.444

Review 6.  beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain.

Authors:  Erica Buoso; Cristina Lanni; Gennaro Schettini; Stefano Govoni; Marco Racchi
Journal:  Pharmacol Res       Date:  2010-05-16       Impact factor: 7.658

7.  A dynamic relationship between intracellular and extracellular pools of Abeta.

Authors:  Salvatore Oddo; Antonella Caccamo; Ian F Smith; Kim N Green; Frank M LaFerla
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

Review 8.  Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome.

Authors:  Shi-Bei Wu; Yi-Shing Ma; Yu-Ting Wu; Yin-Chiu Chen; Yau-Huei Wei
Journal:  Mol Neurobiol       Date:  2010-04-23       Impact factor: 5.590

9.  Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice.

Authors:  Lauren M Billings; Salvatore Oddo; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  Neuron       Date:  2005-03-03       Impact factor: 17.173

10.  Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid beta.

Authors:  G Pigino; G Morfini; Y Atagi; A Deshpande; C Yu; L Jungbauer; M LaDu; J Busciglio; S Brady
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-24       Impact factor: 11.205
View more
  12 in total

1.  RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43.

Authors:  Jacob R Mann; Amanda M Gleixner; Jocelyn C Mauna; Edward Gomes; Michael R DeChellis-Marks; Patrick G Needham; Katie E Copley; Bryan Hurtle; Bede Portz; Noah J Pyles; Lin Guo; Christopher B Calder; Zachary P Wills; Udai B Pandey; Julia K Kofler; Jeffrey L Brodsky; Amantha Thathiah; James Shorter; Christopher J Donnelly
Journal:  Neuron       Date:  2019-02-27       Impact factor: 17.173

Review 2.  The Role of TDP-43 in Alzheimer's Disease.

Authors:  Xiao-Long Chang; Meng-Shan Tan; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-06-17       Impact factor: 5.590

Review 3.  Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.

Authors:  Lindsey R Hayes; Petr Kalab
Journal:  Neurotherapeutics       Date:  2022-07-05       Impact factor: 6.088

4.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

5.  The Neurotoxic TAU45-230 Fragment Accumulates in Upper and Lower Motor Neurons in Amyotrophic Lateral Sclerosis Subjects.

Authors:  Claudia R Vintilescu; Sana Afreen; Ashlee E Rubino; Adriana Ferreira
Journal:  Mol Med       Date:  2016-08-03       Impact factor: 6.354

6.  Folding of the RNA recognition motif (RRM) domains of the amyotrophic lateral sclerosis (ALS)-linked protein TDP-43 reveals an intermediate state.

Authors:  Brian C Mackness; Meme T Tran; Shannan P McClain; C Robert Matthews; Jill A Zitzewitz
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

7.  TDP-43 suppresses tau expression via promoting its mRNA instability.

Authors:  Jianlan Gu; Feng Wu; Wen Xu; Jianhua Shi; Wen Hu; Nana Jin; Wei Qian; Xinglong Wang; Khalid Iqbal; Cheng-Xin Gong; Fei Liu
Journal:  Nucleic Acids Res       Date:  2017-06-02       Impact factor: 16.971

8.  Proteomic analysis of mesenchymal stem cells from normal and deep carious dental pulp.

Authors:  Dandan Ma; Li Cui; Jie Gao; Wenjuan Yan; Ying Liu; Shuaimei Xu; Buling Wu
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

9.  Interaction of transactive response DNA binding protein 43 with nuclear factor κB in mild cognitive impairment with episodic memory deficits.

Authors:  Yasuyuki Ohta; Cyntia Tremblay; Julie A Schneider; David A Bennett; Frederic Calon; Jean-Pierre Julien
Journal:  Acta Neuropathol Commun       Date:  2014-04-01       Impact factor: 7.801

10.  Platelet phosphorylated TDP-43: an exploratory study for a peripheral surrogate biomarker development for Alzheimer's disease.

Authors:  Rodger Wilhite; Jessica M Sage; Abdurrahman Bouzid; Tyler Primavera; Abdulbaki Agbas
Journal:  Future Sci OA       Date:  2017-08-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.